A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
Trial details
- Registry ID
- NCT04854434
- Phase
- Phase 2
The FDA approved Trifluridine on 10 Apr 1980.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsNCT04854434 | KPTI | Phase 2 | Terminated | 2022-06-24Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1980-04-10Day | Trifluridine | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA018299", "applicant_as_listed_by_fda": "MONARCH PHARMS", "brand_names": ["VIROPTIC"], "active_ingredients": ["TRIFLURIDINE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19800410", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |